MX2008012479A - Tratamiento de enfermedades neurodegenerativas. - Google Patents
Tratamiento de enfermedades neurodegenerativas.Info
- Publication number
- MX2008012479A MX2008012479A MX2008012479A MX2008012479A MX2008012479A MX 2008012479 A MX2008012479 A MX 2008012479A MX 2008012479 A MX2008012479 A MX 2008012479A MX 2008012479 A MX2008012479 A MX 2008012479A MX 2008012479 A MX2008012479 A MX 2008012479A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative diseases
- treatment
- methods
- activity
- selenate
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 abstract 1
- 102000001267 GSK3 Human genes 0.000 abstract 1
- 108060006662 GSK3 Proteins 0.000 abstract 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78724006P | 2006-03-29 | 2006-03-29 | |
| PCT/AU2007/000391 WO2007109851A1 (en) | 2006-03-29 | 2007-03-29 | Treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008012479A true MX2008012479A (es) | 2009-08-13 |
Family
ID=38540722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008012479A MX2008012479A (es) | 2006-03-29 | 2007-03-29 | Tratamiento de enfermedades neurodegenerativas. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8920851B2 (https=) |
| EP (1) | EP2004204B1 (https=) |
| JP (1) | JP5542430B2 (https=) |
| KR (1) | KR101451439B1 (https=) |
| CN (1) | CN101478977B (https=) |
| AU (1) | AU2007231547B2 (https=) |
| BR (1) | BRPI0709033A2 (https=) |
| CA (1) | CA2644441C (https=) |
| DK (1) | DK2004204T3 (https=) |
| ES (1) | ES2394348T3 (https=) |
| MX (1) | MX2008012479A (https=) |
| NZ (2) | NZ596244A (https=) |
| RU (1) | RU2489155C2 (https=) |
| WO (1) | WO2007109851A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005276117C1 (en) | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| MX2008012479A (es) | 2006-03-29 | 2009-08-13 | Velacor Therapeutics Pty Ltd | Tratamiento de enfermedades neurodegenerativas. |
| US20080107755A1 (en) * | 2006-04-24 | 2008-05-08 | Alltech, Inc. | Methods and compositions for altering cell function |
| US20100247679A1 (en) * | 2006-04-24 | 2010-09-30 | Alltech, Inc. | Methods and compositions for altering cell function |
| WO2008119109A1 (en) * | 2007-03-29 | 2008-10-09 | Velacor Therapeutics Pty Ltd | Treatment of neurological disorders |
| US8580776B2 (en) * | 2007-07-10 | 2013-11-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods for treating neurodegenerating diseases |
| WO2009039586A2 (en) * | 2007-09-28 | 2009-04-02 | Powmri Limited | Biomarkers for parkinson's disease |
| WO2009043106A1 (en) * | 2007-10-03 | 2009-04-09 | Velacor Therapeutics Pty Ltd | Inorganic selenium and angiogenesis |
| WO2009043116A1 (en) * | 2007-10-03 | 2009-04-09 | Velacor Therapeutics Pty Ltd | Methods and compositions for the treatment of phosphatase- related disorders |
| WO2009065596A2 (en) * | 2007-11-22 | 2009-05-28 | Develogen Aktiengesellschaft | Use of mnk inhibitors for the treatment of alzheimer's disease |
| JP5328244B2 (ja) * | 2008-07-07 | 2013-10-30 | 株式会社ニュージェン・ファーマ | 筋萎縮性側索硬化症治療剤 |
| JP2013507352A (ja) * | 2009-10-09 | 2013-03-04 | テバ ファーマシューティカル インダストリーズ リミティド | 進行性核上性麻痺の治療のためのラサギリンの使用 |
| CA2836503C (en) | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| AU2016235685B2 (en) * | 2015-03-26 | 2019-04-18 | Shanghai Auzone Biological Technology Co., Ltd. | Method of diagnosis or treatment of neurological disorders with p75ECD and/or p75 |
| WO2019216589A1 (ko) * | 2018-05-09 | 2019-11-14 | 한국과학기술연구원 | 타우 관련 질환의 예방 또는 치료용 조성물 |
| KR102846956B1 (ko) * | 2018-06-29 | 2025-08-14 | 리주베나떼 바이오메드 엔브이 | 노화-관련 질환 및/또는 퇴행성 질환에 사용하는 약제학적 결합물 |
| JP7518852B2 (ja) | 2019-03-26 | 2024-07-18 | シアー， インコーポレイテッド | 生物流体からのタンパク質コロナ分析のための組成物、方法およびシステム、ならびにそれらの使用 |
| WO2023029210A1 (zh) * | 2021-08-31 | 2023-03-09 | 上海交通大学医学院附属瑞金医院 | Pp2a激动剂、清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍 |
| WO2023057422A1 (en) * | 2021-10-06 | 2023-04-13 | Bayer Aktiengesellschaft | Universal buffer in methods for safe and rapid detection of pathogen infection |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601915D0 (en) * | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
| JPH04247033A (ja) | 1991-02-04 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | 神経細胞壊死抑制剤 |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5695752A (en) * | 1992-09-11 | 1997-12-09 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
| WO1995024920A1 (en) | 1994-03-16 | 1995-09-21 | The Regents Of The University Of California | Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor |
| US6524619B2 (en) * | 2000-01-27 | 2003-02-25 | Chronorx, Inc. | Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus |
| DE10059886A1 (de) * | 2000-12-01 | 2002-06-20 | Basf Coatings Ag | Verwendung von wässrigen, physikalisch härtbaren Beschichtungsstoffen auf Polyurethanbasis als Haftgrundierung von Lackierungen |
| GB0202900D0 (en) * | 2002-02-07 | 2002-03-27 | Laxdale Ltd | Novel formulations of drugs |
| AU2003262642B2 (en) * | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| BRPI0409914A (pt) | 2003-04-30 | 2006-04-25 | Inst For Pharm Discovery Inc | ácidos carboxìlicos substituìdos |
| AU2003904328A0 (en) | 2003-08-13 | 2003-08-28 | Garvan Institute Of Medical Research | Diagnosis and treatment of neurodegenerative disorders |
| WO2005023274A1 (en) | 2003-09-05 | 2005-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium |
| US20050142216A1 (en) * | 2003-12-31 | 2005-06-30 | Rindlesbach Keith A. | Method for reversing Alzheimer dementia |
| US20080004255A1 (en) * | 2005-10-14 | 2008-01-03 | Alltech, Inc. | Methods and compositions for altering cell function |
| CN101073584B (zh) | 2005-10-14 | 2012-10-10 | 全面技术公司 | 改变细胞功能的方法和组合物 |
| MX2008012479A (es) | 2006-03-29 | 2009-08-13 | Velacor Therapeutics Pty Ltd | Tratamiento de enfermedades neurodegenerativas. |
| EP2004205A4 (en) | 2006-03-29 | 2010-06-09 | Velacor Therapeutics Pty Ltd | INORGANIC SELEN FOR THE TREATMENT OF GOOD TUMORS |
-
2007
- 2007-03-29 MX MX2008012479A patent/MX2008012479A/es active IP Right Grant
- 2007-03-29 RU RU2008142514/15A patent/RU2489155C2/ru not_active IP Right Cessation
- 2007-03-29 BR BRPI0709033-1A patent/BRPI0709033A2/pt not_active IP Right Cessation
- 2007-03-29 AU AU2007231547A patent/AU2007231547B2/en not_active Ceased
- 2007-03-29 CA CA2644441A patent/CA2644441C/en not_active Expired - Fee Related
- 2007-03-29 EP EP07718638A patent/EP2004204B1/en not_active Not-in-force
- 2007-03-29 ES ES07718638T patent/ES2394348T3/es active Active
- 2007-03-29 DK DK07718638.5T patent/DK2004204T3/da active
- 2007-03-29 US US12/295,270 patent/US8920851B2/en not_active Expired - Fee Related
- 2007-03-29 KR KR1020087026561A patent/KR101451439B1/ko not_active Expired - Fee Related
- 2007-03-29 JP JP2009501780A patent/JP5542430B2/ja not_active Expired - Fee Related
- 2007-03-29 CN CN2007800122806A patent/CN101478977B/zh not_active Expired - Fee Related
- 2007-03-29 NZ NZ596244A patent/NZ596244A/xx not_active IP Right Cessation
- 2007-03-29 NZ NZ571835A patent/NZ571835A/en not_active IP Right Cessation
- 2007-03-29 WO PCT/AU2007/000391 patent/WO2007109851A1/en not_active Ceased
-
2013
- 2013-11-14 US US14/079,877 patent/US20140141104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007231547B2 (en) | 2012-07-12 |
| US20090169649A1 (en) | 2009-07-02 |
| KR101451439B1 (ko) | 2014-10-16 |
| EP2004204A1 (en) | 2008-12-24 |
| NZ596244A (en) | 2013-05-31 |
| US20140141104A1 (en) | 2014-05-22 |
| AU2007231547A1 (en) | 2007-10-04 |
| RU2008142514A (ru) | 2010-05-10 |
| EP2004204B1 (en) | 2012-09-12 |
| JP2009532340A (ja) | 2009-09-10 |
| NZ571835A (en) | 2011-11-25 |
| CN101478977A (zh) | 2009-07-08 |
| CN101478977B (zh) | 2013-03-27 |
| JP5542430B2 (ja) | 2014-07-09 |
| EP2004204A4 (en) | 2010-06-02 |
| KR20090015038A (ko) | 2009-02-11 |
| CA2644441A1 (en) | 2007-10-04 |
| US8920851B2 (en) | 2014-12-30 |
| CA2644441C (en) | 2014-09-09 |
| ES2394348T3 (es) | 2013-01-30 |
| DK2004204T3 (da) | 2013-01-07 |
| RU2489155C2 (ru) | 2013-08-10 |
| WO2007109851A1 (en) | 2007-10-04 |
| BRPI0709033A2 (pt) | 2011-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008012479A (es) | Tratamiento de enfermedades neurodegenerativas. | |
| MX2009000285A (es) | Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas. | |
| WO2010059004A3 (ko) | 스네일-p53 간의 결합을 저해하는 화합물 및 이를 유효성분으로 함유하는 암질환 치료제 | |
| MX342128B (es) | Compuestos farmaceuticos. | |
| EA200901486A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| WO2008080082A3 (en) | Methods for modulating set and uses thereof | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| TN2009000291A1 (en) | Inhibitors of mek | |
| WO2010034015A3 (en) | Modulating the alternative complement pathway | |
| JO3358B1 (ar) | معالجات حساسية العيون | |
| MY150650A (en) | Pyrrolopyrimidine compounds and their uses | |
| MX2010003117A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
| MX2009006327A (es) | Compuestos heterociclicos y metodos de uso de los mismos. | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112013008140A2 (pt) | "compostos imidazotriazinona". | |
| WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
| WO2006058868A8 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| EA200901484A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
| TNSN08400A1 (en) | Organic compounds and their uses | |
| HK1206726A1 (en) | Imidazotriazinone compounds | |
| WO2012064897A3 (en) | Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use | |
| MX2010007948A (es) | Inhibidores de proteinas de apoptosis. | |
| WO2007098047A3 (en) | Methods and compositions for the treatment of parkinson's disease | |
| WO2009047513A3 (en) | Antagonists of kisspeptin and uses thereof | |
| WO2008155390A3 (en) | Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |